Braxia Scientific Corp. BRAXF

Company Overview

Braxia Scientific Corp. (CSE: BRAX) is a Canadian healthcare and biotechnology company focused on developing and delivering treatments for depression, post-traumatic stress disorder (PTSD), anxiety disorders, and other mental health conditions. The company operates primarily in the mental health and psychedelic medicine sectors, combining clinical psychiatric services with research into ketamine-assisted therapies and related neurological treatments. Braxia’s activities have historically included patient treatment through specialized clinics as well as clinical research aimed at expanding evidence-based psychiatric care.

The company’s principal revenue drivers have included patient care services delivered through psychiatric and mental health clinics, along with research-related activities tied to psychedelic and ketamine-based treatment models. Braxia evolved from earlier healthcare operations centered on depression treatment and later expanded into psychedelic medicine and neuropsychiatric research during the broader growth of the sector in Canada and internationally. Its strategic positioning has focused on integrating clinical infrastructure with research capabilities, allowing the company to participate in both treatment delivery and emerging therapeutic development markets.